Randomised phase II window study of short term preoperative treatment with the PI3K inhibitor GDC0941 plus Anastrozole versus Anastrozole alone in patients with ERpositive primary breast cancer.

Trial Profile

Randomised phase II window study of short term preoperative treatment with the PI3K inhibitor GDC0941 plus Anastrozole versus Anastrozole alone in patients with ERpositive primary breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Pictrelisib (Primary) ; Anastrozole
  • Indications Breast cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms OPPORTUNE
  • Most Recent Events

    • 14 Mar 2016 Results (n = 75) published in the Journal of Clinical Oncology.
    • 28 Jan 2016 Status changed from recruiting to completed according to United Kingdom Clinical Research Network.
    • 12 Dec 2015 Interim results (n=70) presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top